Inactive Instrument

Actelion Stock

Stocks

ATLN

CH0010532478

Biotechnology & Medical Research

on all subscriptions*

Enjoy this offer

* See conditions under "Our services"

Latest news : Actelion

17-07-31	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
17-07-18	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
17-07-18	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
17-06-09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
17-06-09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
17-06-09	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
17-05-22	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
17-05-18	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
17-04-20	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
17-04-18	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
17-04-05	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
17-03-31	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
17-02-22	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

Press Releases: Actelion

20-04-06	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
17-10-31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
17-06-30	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
17-06-16	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
17-06-15	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

More press releases

News in other languages: Actelion

18-01-29	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
18-01-29	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
18-01-22	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
17-10-31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
17-10-30	Actelion: la décotation est agendée au 7 novembre

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
	ACTELION	-.--%	+0.99%	-	-	0
	ARGENX SE	+3.23%	+2.25%	+65.02%	+113.87%	56.24B
	WUXI APPTEC CO., LTD.	+0.04%	+1.20%	+47.67%	+36.75%	43.76B
	BIONTECH SE	+3.04%	+7.05%	-12.15%	-18.06%	23.32B
	INSMED INCORPORATED	+3.07%	+7.15%	-1.82%	+392.25%	21.34B
	WUXI BIOLOGICS (CAYMAN) INC.	+2.81%	+2.54%	+23.54%	-34.26%	15.75B
	GENMAB A/S	+5.27%	+1.87%	+13.67%	-38.81%	15.6B
	EXELIXIS, INC.	+0.65%	-0.27%	+26.80%	+174.70%	13.18B
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+2.33%	+4.77%	+20.61%	-	12.01B
	PHARMAESSENTIA CORPORATION	+1.92%	+2.43%	+112.68%	+232.59%	11.87B
	Average	+2.25%	+3.15%	+32.89%	+107.38%	23.68B
	Weighted average by Cap.	+2.38%	+2.96%	+37.28%	+98.88%

See all sector performances

Company Profile

Employees

-

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
ATLN Stock

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!